Andrew Mant

542 total citations
16 papers, 130 citations indexed

About

Andrew Mant is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Andrew Mant has authored 16 papers receiving a total of 130 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Andrew Mant's work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (5 papers) and Prostate Cancer Treatment and Research (5 papers). Andrew Mant is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (5 papers) and Prostate Cancer Treatment and Research (5 papers). Andrew Mant collaborates with scholars based in Australia, China and United Kingdom. Andrew Mant's co-authors include Phillip Parente, Georgina V. Long, Victoria Atkinson, Helen Clare Dearden, Nicole Ng, Ian D. Davis, Andrew Haydon, Alexander Guminski, Sayed Ali and Heidi Fettke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Andrew Mant

16 papers receiving 128 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Mant Australia 7 88 43 36 32 27 16 130
Hanna Ronkainen Finland 6 65 0.7× 67 1.6× 64 1.8× 34 1.1× 42 1.6× 11 162
Rachel Roberts‐Thomson Australia 8 74 0.8× 41 1.0× 24 0.7× 20 0.6× 10 0.4× 15 127
Lotus Yung United States 7 89 1.0× 45 1.0× 14 0.4× 38 1.2× 21 0.8× 12 133
Hongqian Wu United States 4 93 1.1× 22 0.5× 29 0.8× 28 0.9× 7 0.3× 6 121
Laura Gibson United States 6 78 0.9× 59 1.4× 62 1.7× 31 1.0× 24 0.9× 6 150
Georgia Makrypidi‐Fraune Germany 6 52 0.6× 50 1.2× 13 0.4× 33 1.0× 18 0.7× 7 125
Anne Song United States 4 30 0.3× 60 1.4× 49 1.4× 8 0.3× 18 0.7× 4 130
Xiaoyan Kang China 7 62 0.7× 49 1.1× 23 0.6× 36 1.1× 21 0.8× 31 140
Adrianna A. Mendes United States 4 74 0.8× 31 0.7× 48 1.3× 75 2.3× 27 1.0× 10 130
Diego Kaen Argentina 4 87 1.0× 24 0.6× 23 0.6× 44 1.4× 27 1.0× 12 115

Countries citing papers authored by Andrew Mant

Since Specialization
Citations

This map shows the geographic impact of Andrew Mant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Mant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Mant more than expected).

Fields of papers citing papers by Andrew Mant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Mant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Mant. The network helps show where Andrew Mant may publish in the future.

Co-authorship network of co-authors of Andrew Mant

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Mant. A scholar is included among the top collaborators of Andrew Mant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Mant. Andrew Mant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Lau, Peter K. H., S.J. Harris, Melissa Eastgate, et al.. (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9525–9525. 1 indexed citations
3.
Clingan, Philip R., Daniel Brungs, Susan Arnold, et al.. (2022). Efficacy and safety of cosibelimab, an anti–PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 9537–9537. 3 indexed citations
4.
5.
Mant, Andrew, et al.. (2021). Checkpoint inhibitor induced steroid refractory drug‐induced liver injury. Internal Medicine Journal. 51(5). 810–811. 3 indexed citations
6.
Fettke, Heidi, Edmond M. Kwan, Patricia Bukczynska, et al.. (2021). Independent prognostic impact of plasma NCOA2 alterations in metastatic castration‐resistant prostate cancer. The Prostate. 81(13). 992–1001. 7 indexed citations
7.
8.
Arance, Ana, Luis de la Cruz‐Merino, Teresa M. Petrella, et al.. (2021). Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. Journal of Clinical Oncology. 39(15_suppl). 9504–9504. 17 indexed citations
9.
Fettke, Heidi, Edmond M. Kwan, Patricia Bukczynska, et al.. (2020). Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer. European Urology Focus. 7(6). 1287–1291. 13 indexed citations
10.
Clingan, P., Daniel Brungs, Rahul Ladwa, et al.. (2020). 1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial. Annals of Oncology. 31. S736–S736. 6 indexed citations
11.
Kwan, Edmond M., Heidi Fettke, Maria Docanto, et al.. (2019). Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. European Urology Focus. 7(1). 63–70. 11 indexed citations
12.
Mason, Robert M., Helen Clare Dearden, Jessica L. Smith, et al.. (2019). Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma. Pigment Cell & Melanoma Research. 33(2). 358–365. 38 indexed citations
13.
Fettke, Heidi, Edmond M. Kwan, Andrew Mant, et al.. (2018). Plasma Cell-Free DNA (cfDNA) Concentration and Outcomes in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients Treated with Androgen Receptor Signalling Inhibitors (ARSIs). Asia-Pacific Journal of Clinical Oncology. 14. 29–29. 1 indexed citations
14.
To, Sarah Q., Edmond M. Kwan, Heidi Fettke, et al.. (2018). Abstract 2593: AR-V7 and AR-V9 expression is not predictive of response to AR-axis targeting agents in metastatic castration-resistant prostate cancer. Cancer Research. 78(13_Supplement). 2593–2593. 1 indexed citations
15.
Xu, Wen, Spiros Fourlanos, Alison Nankervis, et al.. (2018). Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabetic Medicine. 35(9). 1283–1290. 24 indexed citations
16.
Dearden, Helen Clare, Robert M. Mason, Jessica L. Smith, et al.. (2018). Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients. Annals of Oncology. 29. viii448–viii448. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hanna Ronkainen Breakdown of academic impact, for papers by Rachel Roberts‐Thomson Breakdown of academic impact, for papers by Lotus Yung Breakdown of academic impact, for papers by Hongqian Wu Breakdown of academic impact, for papers by Laura Gibson Breakdown of academic impact, for papers by Georgia Makrypidi‐Fraune Breakdown of academic impact, for papers by Anne Song Breakdown of academic impact, for papers by Xiaoyan Kang Breakdown of academic impact, for papers by Adrianna A. Mendes Breakdown of academic impact, for papers by Diego Kaen
Rankless by CCL
2026